ScreenerHero

PYC PYC Therapeutics Limited

ASX · AU · Healthcare · Biotechnology · pyctx.com
—Mkt Cap: —P/E: —

PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.87BUSDP/E 29.6
MRNA
Moderna, Inc.
$94.42BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$81.99BUSDP/E 19.1
ARGX
argenx SE
$53.47BUSDP/E 32.5
ARGX
argenx SE
$53.22BUSDP/E 31.6
UCB
UCB SA
$44.02BUSDP/E 17.8
ONC
BeOne Medicines AG
$42.56BUSDP/E 66.4
RVMD
Revolution Medicines, Inc.
$40.57BUSD
RPRX
Royalty Pharma plc
$34.45BUSDP/E 30.4
ALNY
Alnylam Pharmaceuticals, Inc.
$31.32BUSDP/E 39.3
ROIV
Roivant Sciences Ltd.
$24.59BUSD
GMAB
Genmab A/S
$23.32BUSDP/E 31.7
GMAB
Genmab A/S
$23.26BUSDP/E 29.8
INCY
Incyte Corporation
$22.96BUSDP/E 14.0
BNTX
BioNTech SE
$22.66BUSD
INSM
Insmed Incorporated
$21.67BUSD
EXEL
Exelixis, Inc.
$15.57BUSDP/E 19.3
ASND
Ascendis Pharma A/S
$14.91BUSDP/E 17.4
JAZZ
Jazz Pharmaceuticals plc
$13.92BUSDP/E 14.7
HALO
Halozyme Therapeutics, Inc.
$13.79BUSDP/E 33.4

Key Statistics

Company
Market Cap—
Enterprise Value948.56M USD
Revenue (TTM)17.96M USD
Gross Profit17.96M USD
Net Income (TTM)-29.95M USD
Revenue/Share0.04 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000PYC7
Valuation
P/E (Trailing)—
P/E (Forward)-21.16
PEG—
EV/EBITDA-24.25
EV/Revenue52.80
P/S68.91
P/B2.58
EPS (TTM)-0.06
EPS (Forward)-0.09
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-188.25%
EBITDA Margin-217.71%
Profit Margin-166.73%
ROE-6.25%
ROA-6.12%
Growth
Revenue Growth46.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.77M USD
CapEx (TTM)367.24K USD
FCF Margin-154.24%
FCF Yield—
Net Debt-308.87M USD
Net Debt/EBITDA7.90
Balance Sheet
Debt/Equity0.00
Current Ratio33.48
Quick Ratio33.44
Book Value/Sh0.70 AUD
Cash/Share0.46 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateNov 15, 2024
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.998 AUD
Target Range2.840 AUD – 5.000 AUD
# Analysts5
Ownership
Shares Out.984.21M
Float618.49M
Insiders33.81%
Institutions18.11%
Technical
SMA 502.374 AUD
SMA 2001.681 AUD
Beta1.01
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)3.12M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—